PIFLUFOLASTAT

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H23FN4O8
Molecular Weight	442.3956
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)C1=CC=C(F)N=C1)C(O)=O)C(O)=O

InChI

InChIKey=OLWVRJUNLXQDSP-RYUDHWBXSA-N

InChI=1S/C18H23FN4O8/c19-13-6-4-10(9-21-13)15(26)20-8-2-1-3-11(16(27)28)22-18(31)23-12(17(29)30)5-7-14(24)25/h4,6,9,11-12H,1-3,5,7-8H2,(H,20,26)(H,24,25)(H,27,28)(H,29,30)(H2,22,23,31)/t11-,12-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C18H23FN4O8
Molecular Weight	442.3956
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://pubmed.ncbi.nlm.nih.gov/34292532|https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214793s000lbl.pdf

Piflufolastat F 18 (PYLARIFY®) is an 18F-labelled diagnostic imaging agent that has been developed by Progenics Pharmaceuticals Inc., a Lantheus company, for positron emission tomography (PET) that targets prostate-specific membrane antigen (PSMA). Piflufolastat F 18 binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. Fluorine-18 (F 18) is a β emitting radionuclide that enables positron emission tomography. Piflufolastat F 18 was approved in the USA on 27 May 2021 for PET of PSMA positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum prostate specific antigen (PSA) level.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glutamate carboxypeptidase II 26 Target ID: CHEMBL1892 Sources: https://pubmed.ncbi.nlm.nih.gov/32097010\|https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214793s000lbl.pdf	Inhibitor 8504		1.56 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Prostate cancer 186 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214793s000lbl.pdf	Primary		Approved 8583	PYLARIFY Approved Use PYLARIFY is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: • with suspected metastasis who are candidates for initial definitive therapy. • with suspected recurrence based on elevated serum prostatespecific antigen (PSA) level. Launch Date 2021

T_1/2

Value	Dose	Co-administered	Analyte	Population
3.47 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214793s000lbl.pdf#page=7	333 MBq single, intravenous dose: 333 MBq route of administration: Intravenous experiment type: SINGLE co-administered:		DCFPYL plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
			inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214793Orig1s000MultidisciplineR.pdf#page=38 Page: 38.0

PubMed

Title	Date	PubMed
Nodular Fasciitis: False Positive on 18F-Piflufolastat and 11C-Choline PET/CT.	2023-04-01	36728209
Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer .	2022-07	35603510
Piflufolastat F 18: Diagnostic First Approval.	2021-09	34292532

Patents

Sample Use Guides

In Vivo Use Guide

Recommended dose is 333 MBq (9 mCi) with an acceptable range of 296 MBq to 370 MBq (8 mCi to 10 mCi), administered as a bolus intravenous injection. Initiate imaging approximately 60 minutes after PYLARIFY administration. The patient should void immediately prior to initiation of imaging. Image acquisition should start from mid-thigh and proceed to the skull vertex.

Route of Administration: Intravenous

In Vitro Use Guide

DCFPyL inhibited PSMA in human LNCaP cell extracts in presence of N-acetylaspartylglutamate by Amplex red glutamic acid dependent fluorescence-based NAALADase assay with IC50 1.56 nM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:28:58 GMT 2025` Edited by `admin` on `Mon Mar 31 21:28:58 GMT 2025`
Record UNII	82VH67YON8
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PIFLUFOLASTAT

Common Name

English

DCFPYL

Preferred Name

English

2-(3-(1-CARBOXY-5-((6-FLUORO-PYRIDINE-3-CARBONYL)-AMINO)-PENTYL)-UREIDO)-PENTANEDIOIC ACID

Systematic Name

English

L-GLUTAMIC ACID, N-((((1S)-1-CARBOXY-5-(((6-FLUORO-3-PYRIDINYL)CARBONYL)AMINO)PENTYL)AMINO)CARBONYL)-

Systematic Name

English

Code System Code Type Description

WIKIPEDIA

Piflufolastat F-18